Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,941,276
  • Shares Outstanding, K 102,065
  • Annual Sales, $ 0 K
  • Annual Income, $ -846,420 K
  • EBIT $ -885 M
  • EBITDA $ -877 M
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.58

Options Overview Details

View History
  • Implied Volatility 98.40% ( -11.76%)
  • Historical Volatility 119.30%
  • IV Percentile 66%
  • IV Rank 39.22%
  • IV High 167.90% on 04/21/25
  • IV Low 53.57% on 08/16/24
  • Put/Call Vol Ratio 0.24
  • Today's Volume 499
  • Volume Avg (30-Day) 3,090
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 46,341
  • Open Int (30-Day) 35,888

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.67
  • Number of Estimates 10
  • High Estimate -1.30
  • Low Estimate -1.92
  • Prior Year -2.20
  • Growth Rate Est. (year over year) +24.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.79 +28.25%
on 04/09/25
24.06 -15.84%
on 05/02/25
+3.71 (+22.43%)
since 04/08/25
3-Month
15.79 +28.25%
on 04/09/25
44.28 -54.27%
on 02/11/25
-18.18 (-47.31%)
since 02/07/25
52-Week
15.79 +28.25%
on 04/09/25
55.70 -63.64%
on 10/08/24
-20.53 (-50.34%)
since 05/08/24

Most Recent Stories

More News
Why BioHaven Stock Is Soaring Today

Shares of Biohaven (NYSE: BHVN) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 traded mixed...

COMP : 7.73 (+1.05%)
NFLX : 1,144.43 (-0.95%)
BHVN : 20.25 (+6.47%)
Why Biohaven Stock Plummeted by More Than 15% Today

On Friday's news that Biohaven (NYSE: BHVN) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage biotech...

NFLX : 1,144.43 (-0.95%)
BHVN : 20.25 (+6.47%)
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March

Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX) , and CRISPR Therapeutics (NASDAQ: CRSP) , plunged in March, with the stocks down 35.3%,...

BHVN : 20.25 (+6.47%)
CRSP : 36.14 (+5.52%)
RXRX : 4.39 (+4.77%)
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

BHVN : 20.25 (+6.47%)
COLL : 27.27 (+0.81%)
TRVI : 6.60 (-0.90%)
AVTX : 4.35 (-2.25%)
Company News for Mar 4, 2025

California Resources Corp.’s (CRC) shares plummeted 11.7% after posting fourth-quarter 2024 adjusted earnings per share of $0.91, missing the Zacks Consensus Estimate of $0.34.Shares of TG Therapeutics...

TGTX : 33.86 (-2.84%)
BHVN : 20.25 (+6.47%)
CRC : 40.71 (+5.82%)
NOMD : 19.41 (+1.46%)
Why Biohaven Stock Triumphed on Tuesday

News of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug is...

BHVN : 20.25 (+6.47%)
Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish

Earlier this month, Biohaven reported achieving important milestones in the trial of its experimental drug BHV-1300, which is intended for use in the treatment of kidney disease.

BHVN : 20.25 (+6.47%)
Biohaven’s SMA Trial Miss Bolsters Scholar Rock Stock: Analysts Give Verdicts, Retail Watches Closely

Last month, Scholar Rock achieved the primary endpoint in the company's own Phase 3 trial of apitegromab in SMA patients.

BHVN : 20.25 (+6.47%)
VTI : 278.28 (+0.79%)
SRRK : 30.99 (+4.34%)
IWM : 201.18 (+1.90%)
XBI : 78.04 (+0.89%)
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

Shares of Scholar Rock SRRK skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted...

BHVN : 20.25 (+6.47%)
ANIP : 71.53 (+1.00%)
CPRX : 22.76 (-2.98%)
SRRK : 30.99 (+4.34%)
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Shares of Biohaven Ltd. BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for...

BHVN : 20.25 (+6.47%)
KRYS : 137.17 (+0.27%)
FULC : 5.41 (+6.71%)
ANIP : 71.53 (+1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut....

See More

Key Turning Points

3rd Resistance Point 23.70
2nd Resistance Point 22.41
1st Resistance Point 21.33
Last Price 20.25
1st Support Level 18.96
2nd Support Level 17.67
3rd Support Level 16.59

See More

52-Week High 55.70
Fibonacci 61.8% 40.45
Fibonacci 50% 35.74
Fibonacci 38.2% 31.04
Last Price 20.25
52-Week Low 15.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar